Tech Company Financing Transactions

Alder Biopharmaceuticals Funding Round

Alder Biopharmaceuticals, based in Bothell, secured $38 million in funding from Novo Ventures, Delphi Ventures and H.I.G. Capital.

Transaction Overview

Company Name
Alder Biopharmaceuticals
Announced On
4/19/2012
Transaction Type
Venture Equity
Amount
$38,000,000
Round
Series D
Investors

Novo Ventures (Lead Investor) (Peter Bisgaard)

Delphi Ventures (Deepa Pakianathan)

H.I.G. Capital

Sevin Rosen Funds (Steven Dow)

TPG Biotech (Heather Preston)

Ventures West

WRF Capital (Thong Le)

Proceeds Purpose
Proceeds of the financing will support clinical development of ALD518 and ALD403. ALD518, a monoclonal antibody to the pro-inflammatory cytokine IL-6, is currently being investigated in ongoing Phase 2 clinical studies in cancer related indications, which were retained by the company in its partnership with Bristol-Myers Squibb in 2009.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
11804 North Creek Pkwy. South
Bothell, WA 98011
USA
Phone
(425) 205-2900
Website
www.alderbio.com
Email Address
[email protected]
Overview
Alder focuses on developing its pipeline of therapeutic candidates that leverage its proprietary monoclonal antibody discovery and manufacturing technologies.
Profile
Alder Biopharmaceuticals LinkedIn Company Profile
Social Media
Alder Biopharmaceuticals Company Twitter Account
Company News
Alder Biopharmaceuticals News
Facebook
Alder Biopharmaceuticals on Facebook
YouTube
Alder Biopharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Robert Azelby
  Robert Azelby LinkedIn Profile  Robert Azelby Twitter Account  Robert Azelby News  Robert Azelby on Facebook
Chief Financial Officer
Carlos Campoy
  Carlos Campoy LinkedIn Profile  Carlos Campoy Twitter Account  Carlos Campoy News  Carlos Campoy on Facebook
Chief Medical Officer
Paul Streck
  Paul Streck LinkedIn Profile  Paul Streck Twitter Account  Paul Streck News  Paul Streck on Facebook
Chief Operating Officer
Erin Lavelle
  Erin Lavelle LinkedIn Profile  Erin Lavelle Twitter Account  Erin Lavelle News  Erin Lavelle on Facebook
VP - Bus. Development
Nadia Dac
  Nadia Dac LinkedIn Profile  Nadia Dac Twitter Account  Nadia Dac News  Nadia Dac on Facebook
VP - General Counsel
James Bucher
  James Bucher LinkedIn Profile  James Bucher Twitter Account  James Bucher News  James Bucher on Facebook
VP - Operations
Randy Hassler
  Randy Hassler LinkedIn Profile  Randy Hassler Twitter Account  Randy Hassler News  Randy Hassler on Facebook
VP - Regulatory Affairs
Annette Vahratian
  Annette Vahratian LinkedIn Profile  Annette Vahratian Twitter Account  Annette Vahratian News  Annette Vahratian on Facebook

 

 

Browse more venture capital transactions:

Prev: 4/19/2012: Privia Health venture capital transaction
Next: 4/20/2012: Neighborland venture capital transaction

 

Share this article

 

About Database of VC Transactions

We do our best to document all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.